Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,725 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Oct 6, 2023 |
| clinicaltrials |
| NCT06037135 | Dexmedetomidine Infusion During Laparoscopic Adrenalectomy | completed | N/A | 40 | Yonsei UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067594 | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | completed | — | 155 | Austral University, ArgentinaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068101 | Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | completed | — | 274 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT05871320 | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms(TECANT) | completed | Early Phase 1 | 10 | Jagiellonian UniversityOTHER | 3 | Sep 29, 2023 | clinicaltrials |
| NCT00856037 | Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 22 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06053437 | Prognostic Indicators in Pituitary Adenoma Surgery: a Comprehensive Analysis of Surgical Outcomes and Complications.(Hyp'Op) | completed | — | 211 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05942482 | Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey | completed | — | 39 | Pamukkale UniversityOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01659385 | Leptin Levels in Papillary Thyroid Cancer(LL-PTC) | completed | — | 18 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03216343 | Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer | completed | Phase 1 | 48 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT01782443 | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT05026593 | A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 60 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02267603 | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04385992 | Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET(NeoLuPaNET) | completed | Phase 2 | 31 | IRCCS San RaffaeleOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05873283 | Papillary Thyroid Cancer and Central Lymp Node Dissection | completed | — | 250 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 1 | May 24, 2023 | clinicaltrials |
| NCT05171517 | Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT04452292 | Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma(PRECISION-NEC) | completed | N/A | 2 | Charles KunosOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT01440816 | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer(MCC) | completed | Phase 2 | 15 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05858177 | The Efficacy and Safety of Temozolomide in Patients With MPPGL(MPPGL) | completed | Phase 2 | 62 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT03136328 | Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan | completed | Phase 3 | 11 | Montefiore Medical CenterOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT05816720 | Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) | completed | — | 31 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04212793 | Detection of PitNET Tissue During TSS Using Bevacizumab-800CW(DEPARTURE) | completed | Phase 1 | 20 | University Medical Center GroningenOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05803330 | Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma | completed | N/A | 95 | Kunwu Yan,MMOTHER | 0 | Apr 7, 2023 | clinicaltrials |
| NCT02186678 | Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation(DOTATATE) | completed | N/A | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT00442533 | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 200 | Radio Isotope Therapy of AmericaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | completed | Phase 3 | 219 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 195 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01237457 | 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms | completed | Phase 2 | 143 | Ebrahim S DelpassandOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04922801 | Optimising Molecular Radionuclide Therapy(SELFIE) | completed | — | 50 | King's College LondonOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05344027 | The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma(MitoS-FP) | completed | — | 35 | King's College Hospital NHS TrustOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT01253161 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03918759 | Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs | completed | — | 100 | IRCCS San RaffaeleOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04672928 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | completed | Phase 1 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05311800 | High-Intensity Interval Training and Fat Mass Losses(RIESLING) | completed | N/A | 9 | Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et PathologiquesOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02753686 | Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy(Treat ER+ight) | completed | — | 440 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT00001345 | Studies of Inherited Diseases of Metabolism | completed | — | 969 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05673798 | Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients | completed | — | 569 | The Second Hospital of Shandong UniversityOTHER | 0 | Jan 10, 2023 | clinicaltrials |
| NCT05285033 | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC(LURBICLIN) | completed | — | 312 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05671393 | the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma | completed | — | 801 | Fujian Medical UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2023source: clinicaltrials